$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Analysis of potential risks of Tepotinib (Tuodekang) in the treatment of metastatic non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Analysis of the mechanism of action and targeted signaling pathways of regorafenib (Belvango)
2026-02-01 22:25:32
Check Details
Pazopanib (Pazopanib) belongs to which generation of targeted drugs and introduction to its clinical advantages
2026-02-01 22:25:32
Check Details
Contraindications and risk groups for taking Opicapone
2026-02-01 22:25:32
Check Details
Full analysis of the side effects of Fenelidone (Keshenda) and how to deal with them
2026-02-01 22:25:32
Check Details
Analysis of the actual clinical effect of rasagiline (Azilai) in the treatment of Parkinson's disease
2026-02-01 22:25:32
Check Details
Six major contraindications and medication safety reminders for taking Mavakatai (Mefanto)
2026-02-01 22:25:32
Check Details
Can I stop taking tenofovir alafenamide tablets (Vemlidy) once I start taking it?
2026-02-01 22:25:32
Check Details
Interpretation of whether vorasidenib-VORANIGO has been included in medical insurance and reimbursement policies
2026-02-01 22:25:32
Check Details
The latest selling price of eflornithine (IWILFIN) tablets and price comparison across different channels
2026-02-01 22:25:32
Check Details
The specific mechanism of action of odexibat (Belvi) and its mechanism of efficacy in the body
2026-02-01 22:25:32
Check Details
The mechanism of action of donepezil (Aricept) on improving brain cognition and memory function
2026-02-01 22:25:32
Check Details
1
2
...
1945
1946
1947
1948
1949
1950
1951
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma